Autoimmune Idiopathic Inflammatory Myopathies: Pharmacological Differences and Similarities by Type of Myositis and by Sociodemographic Variables

Table 3

Comparison of some sociodemographic and pharmacological variables between age groups of patients diagnosed with autoimmune idiopathic inflammatory myopathies in Colombia.

Variables	<65 years		≥65 years
		%		%
Woman	334	69.4	142	74.7	0.173
Type of inflammatory myopathy	—	—	—	—	—
Overlap myositis	141	29.3	70	36.8	0.058
Polymyositis	136	28.3	62	32.6	0.265
Other dermatomyositis	112	23.3	33	17.4	0.093
Dermatopolymyositis	88	18.3	25	13.2	0.109
Juvenile dermatomyositis	4	0.8	0	0.0	0.582
Comorbidities	358	74.4	177	93.2	<0.001
Arterial hypertension	134	27.9	115	60.5	<0.001
Diabetes mellitus	67	13.9	72	37.9	<0.001
Hypothyroidism	65	13.5	59	31.1	<0.001
Rheumatoid arthritis	74	15.4	45	23.7	0.011
Chronic pain	49	10.2	28	14.7	0.096
Infections	107	22.2	50	26.3	0.262
Pharmacotherapy	440	91.5	174	91.6	0.966
Systemic glucocorticoids	381	79.2	146	76.8	0.501
Prednisolone	292	60.7	122	64.2	0.400
Prednisone	112	23.3	37	19.5	0.285
Dexamethasone	92	19.1	27	14.2	0.133
Methylprednisolone	40	8.3	12	6.3	0.383
Pulses	7	1.5	3	1.6	1.000
Deflazacort	34	7.1	13	6.8	0.918
Betamethasone	22	4.6	8	4.2	0.837
Hydrocortisone	7	1.5	3	1.6	1.000
Conventional DMARDs	346	71.9	151	79.5	0.045
Azathioprine	233	48.4	94	49.5	0.809
Methotrexate	166	34.5	76	40.0	0.182
Chloroquine	86	17.9	19	10.0	0.011
Hydroxychloroquine	25	5.2	7	3.7	0.407
Sulfasalazine	3	0.6	3	1.6	0.359
Leflunomide	4	0.8	1	0.5	1.000
Immunosuppressants	50	10.4	11	5.8	0.062
Mycophenolate	21	4.4	3	1.6	0.105
Cyclosporine	16	3.3	5	2.6	0.641
Cyclophosphamide	18	3.7	3	1.6	0.217
Human immunoglobulin	5	1.0	0	0.0	0.329
Biological DMARDs	21	4.4	4	2.1	0.256
Rituximab	17	3.5	4	2.1	0.462
Others ()^	4	0.8	0	0.0	0.582
Comedications	—	—	—	—	—
Analgesics	313	65.1	136	71.6	0.107
Antiulcer	287	59.7	126	66.3	0.111
Antihypertensives and diuretics	164	34.1	124	65.3	<0.001
Nonsteroidal anti-inflammatory drugs	215	44.7	68	35.8	0.035
Antihistamines	185	38.5	57	30.0	0.040

Fisher’s exact test. DMARD: disease-modifying antirheumatic drugs. ^Others: adalimumab, abatacept, belimumab, and certolizumab.